Insertion of Copper T380 Versus Multiload IUD Post Partum
Launched by MAHMOUD ABDELHAMEED HUSSIEN SOLIMAN · Mar 8, 2022
Trial Information
Current as of May 11, 2025
Unknown status
Keywords
ClinConnect Summary
Insertion of an intrauterine device (IUD) immediately after delivery is appealing for several reasons. The woman is known not to be pregnant, her motivation for contraception may be high, and the setting may be convenient for both the woman and her provider The World Health Organization (WHO) recommends that a woman should wait at least 24 months after delivery before the next pregnancy to decrease the adverse maternal, perinatal ,and infant outcomes.
Compared with other contraceptive methods, early post-partum IUD insertion has several advantages. It provides immediate contraception witho...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • women delivered by elective CS ≥ 36 wks
- Exclusion Criteria:
- • Patients with PROM Patients on corticosteroids therapy Patients on anticoagulant patients who refuse participate in the study with written consent
About Mahmoud Abdelhameed Hussien Soliman
Mahmoud Abdelhameed Hussien Soliman is a dedicated clinical trial sponsor with a focus on advancing medical research and improving patient outcomes. With extensive experience in the clinical research landscape, he emphasizes adherence to regulatory standards and ethical practices. His commitment to innovation drives the development of safe and effective therapeutic solutions, fostering collaborations with healthcare professionals and institutions. Through meticulous oversight and a passion for scientific excellence, Soliman strives to contribute meaningfully to the evolving field of medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials